Published in Circ Arrhythm Electrophysiol on August 01, 2013
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Hypothalamic mTOR signaling regulates food intake. Science (2006) 8.62
Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science (2009) 7.80
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A (2005) 7.21
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell (2003) 6.76
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol (2004) 6.00
Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science (2007) 5.19
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab (2006) 4.98
mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science (2010) 4.81
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet (2010) 4.29
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol (2003) 4.20
Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation (2004) 4.13
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet (2004) 3.88
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet (2009) 3.86
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
A public resource facilitating clinical use of genomes. Proc Natl Acad Sci U S A (2012) 3.72
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science (2003) 3.71
Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med (2005) 3.71
mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med (2007) 3.66
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 3.59
Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail (2009) 3.54
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest (2010) 3.47
Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med (2010) 3.42
Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med (2016) 3.40
The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet (2005) 3.36
Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest (2002) 3.33
Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A (2007) 3.32
Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol (2004) 3.20
Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
Amino acids activate mTOR complex 1 via Ca2+/CaM signaling to hVps34. Cell Metab (2008) 2.96
Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. Genes Dev (2002) 2.87
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Genetic causes of human heart failure. J Clin Invest (2005) 2.79
Filter-based hybridization capture of subgenomes enables resequencing and copy-number detection. Nat Methods (2009) 2.71
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res (2004) 2.64
Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. J Clin Invest (2010) 2.64
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2011) 2.53
Predictive value of microvolt T-wave alternans in patients with left ventricular dysfunction. J Am Coll Cardiol (2007) 2.49
Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A (2006) 2.46
Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol (2002) 2.46
Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet (2012) 2.39
Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays (2002) 2.37
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
dS6K-regulated cell growth is dPKB/dPI(3)K-independent, but requires dPDK1. Nat Cell Biol (2002) 2.31
Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol (2009) 2.30
Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation (2003) 2.28
AMP-activated protein kinase in the heart: role during health and disease. Circ Res (2007) 2.27
Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet (2002) 2.27
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol (2009) 2.22
The future of fellowship training in clinical cardiac electrophysiology: Program directors' perspective 2008. Heart Rhythm (2009) 2.22
Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol (2007) 2.18
A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell (2007) 2.12
Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med (2008) 2.12
Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res (2011) 2.05
Usefulness of precordial T-wave inversion to distinguish arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia arising from the right ventricular outflow tract. Am J Cardiol (2010) 2.02
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol (2008) 2.01
The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett (2006) 1.97
Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet (2002) 1.93
Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation (2002) 1.91
Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. Dev Biol (2006) 1.91
Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet (2013) 1.91
Genetics of congenital heart disease: the glass half empty. Circ Res (2013) 1.90
Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus. Neurosurgery (2005) 1.87
S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J Biol Chem (2008) 1.87
Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting. Anesthesiology (2009) 1.85
Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol (2010) 1.83
Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet (2005) 1.80
Right and left ventricular outflow tract tachycardias: evidence for a common electrophysiologic mechanism. J Cardiovasc Electrophysiol (2006) 1.78
Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA (2009) 1.75
Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science (2013) 1.75
S6K1 plays a critical role in early adipocyte differentiation. Dev Cell (2010) 1.74
S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol (2009) 1.74
Contemporary evaluation and management of hypertrophic cardiomyopathy. Circulation (2002) 1.73
Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation (2008) 1.72
Signaling control of mRNA translation in cancer pathogenesis. Oncogene (2004) 1.71
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2011) 1.70
Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation (2005) 1.68